TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30536161
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (0.9% NaCl)
Study: 28082531
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg or 1200 mg
Study: 28082531
Drug: Aspirin 24
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 24 mg
Study: 21317203
Drug: Trastuzumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab monotherapy in step 1
Study: 21317203
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trastuzumab and letrozole in step 2
Study: 12638399
Drug: Oxycodone 10
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10 mg/Acetaminophen 325 mg (Percocet)
Study: 12638399
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone 20 mg (OxyContin)
Study: 11347285
Drug: Zinc oxide/glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc oxide/glycine cream
Study: 31722152
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg, orally, twice daily for 12 weeks
Study: 31722152
Drug: Placebo, orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, twice daily for 12 weeks
Study: 31926340
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg
Study: 21740540
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to initial treatment
Study: 7805356
Drug: Standard drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drugs
Study: 10385494
Drug: Etanercept (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (4 or 10 mg/m2)
Study: 6407378
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three antibiotics
Study: 30725315
Drug: Loxoprofen Hydrogel
Normalized name: loxoprofen
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen Hydrogel Transdermal Patch (LOX-T)
Study: 30725315
Drug: Loxoprofen Tablet
Normalized name: loxoprofen
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxoprofen Tablet (LOX-O)
Study: 8818846
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg) administered as a single dose 12, 24 or 48 h before tympanostomy tubes insertion in 17 children with secretory otitis media
Study: 8818846
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg on day 1, 5 mg/kg on days 2-5) administered once daily for 5 days in 12 children with acute otitis media
Study: 6489326
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ciprofloxacin (250 mg)
Study: 6489326
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of ciprofloxacin (100 mg)
Study: 3777908
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intravenous administration of ciprofloxacin
Study: 2868030
Drug: Propranolol (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (full beta-receptor blockade)
Study: 2868030
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol and diltiazem, 240 mg/day
Study: 2868030
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol and diltiazem, 360 mg/day
Study: 2868030
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (low dose)
Study: 2868030
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (high dose)
Study: 2868030
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose diltiazem combination
Study: 24670079
Drug: Multidisciplinary inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary inpatient treatment at the Dutch Asthma Center in Davos, Switzerland for six weeks
Study: 24670079
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment at the outpatient clinic of the Wilhelmina Children's Hospital, Utrecht, the Netherlands for six weeks
Study: 10566642
Drug: 131I plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 131I plus pretreatment with methimazole (30 mg/day; 23 patients)
Study: 1829901
Drug: Ser‐Tyr28 human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under low potassium diet (LK)
Study: 1829901
Drug: Ser‐Tyr28 human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under low salt diet (LS)
Study: 1829901
Drug: Ser‐Tyr28 human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under high potassium diet (HK)
Study: 31591119
Drug: Nafithromycin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafithromycin (100 to 1200 mg) under fasted or fed condition
Study: 31591119
Drug: Nafithromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafithromycin (400 and 800 mg) under fed condition
Study: 31591119
Drug: Nafithromycin (600,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafithromycin (600, 800, or 1000 mg) once daily for 7 days under fed condition
Study: 31591119
Drug: Nafithromycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafithromycin (600 mg and 800 mg)
Study: 31591119
Drug: Nafithromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafithromycin (1000 mg)
Study: 31591119
Drug: Nafithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafithromycin (single and multiple dosing)
Study: 28605411
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine content (VLNC) cigarettes; specific dosage and duration not mentioned.
Study: 24583274
Drug: Integrated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated intervention (n=48): six individual treatment visits plus eight weeks of nicotine patch therapy integrated with binge drinking intervention
Study: 24583274
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n=47): six individual treatment visits plus eight weeks of nicotine patch therapy
Study: 17663100
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Fengchi (GB 20), Quchi (LI 11), Neiguan (PC 6), Zusanli (ST 36), Fenglong (ST 40), Taicehong (LR 3) and oral administration of Captoril
Study: 9222075
Drug: Trovafloxacin 200
Normalized name: trovafloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 200 mg in the morning and placebo in the evening (group A)
Study: 9222075
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily (group B)
Study: 28793989
Drug: Enteral tube
Normalized name: ENTERAL TUBE DECLOGGER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral tube feeding for ≥7 days in addition to standard care (intravenous rehydration and antiemetic treatment)
Study: 28793989
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care alone (intravenous rehydration and antiemetic treatment)
Study: 22850935
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D(3) supplementation (20,000 IU weekly)
Study: 20950168
Drug: Anodyne® treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anodyne® treatment
Study: 20950168
Drug: HealthLight™ treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HealthLight™ treatment
Study: 7950228
Drug: Puji ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puji ointment (PJO)
Study: 26889617
Drug: Cabbage Leaf
Normalized name: cabbage leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabbage Leaf Wraps (CLWs) for 4 weeks (daily for at least 2 hours)
Study: 26889617
Drug: Topical Pain
Normalized name: Flex24 Topical Pain Patch
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical Pain Gel (TPG) (10 mg diclofenac/g, at least once daily)
Study: 23744798
Drug: Nicotine (gum,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (gum, 6 mg)
Study: 19057883
Drug: DMARD or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMARD or TNF-alpha-inhibitors
Study: 15327421
Drug: 0.25 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mmol/L dMg, 1.25 mmol/L dCa (group IV)
Study: 15327421
Drug: 0.75 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mmol/L dMg, 1.25 mmol/L dCa
Study: 15327421
Drug: 0.25 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mmol/L dMg, 1.75 mmol/L dCa (group II)
Study: 15327421
Drug: 0.75 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mmol/L dMg, 1.75 mmol/L dCa (group I)
Study: 15327421
Drug: 0.75 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mmol/L dMg, 1.25 mmol/L dCa (group III)
Study: 2754052
Drug: Interferon alfa‐nl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐nl, 5 million units, subcutaneously daily for 2 weeks then twice weekly for 4 weeks
Study: 2754052
Drug: Isotretinoin, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin, 1 mg/kg by mouth daily for 6 weeks
Study: 2754052
Drug: Combination treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment: interferon therapy three times weekly in combination with daily isotretinoin for 6 weeks
Study: 2754052
Drug: Sequential treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment: those whose clearing was incomplete with interferon alone were switched to interferon three times weekly for 6 weeks
Study: 792993
Drug: Salbutamol tablets
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol tablets (4 mg)
Study: 792993
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of salbutamol tablets and aerosols
Study: 792993
Drug: Combined active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined active treatment
Study: 27452896
Drug: Standard SGI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard SGI (12 sessions, twice weekly)
Study: 25447201
Drug: Probiotics administered
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administered to 5 infants
Study: 25447201
Drug: No probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No probiotics administered to 38 infants
Study: 8942402
Drug: low‐dose phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐dose phentolamine
Study: 8942402
Drug: high‐dose phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: high‐dose phentolamine
Study: 11524329
Drug: control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (no drug)
Study: 1749945
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg gold sodium thiomalate (GST) administered intramuscularly for 12 months
Study: 1749945
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg methotrexate (MTX) administered intramuscularly for 12 months
Study: 7200736
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) infusion (100‐150 ng/kg/minute)
Study: 26867477
Drug: Mallinckrodt tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mallinckrodt tube (ML)
Study: 19862403
Drug: Various sealants
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various sealants and adhesive agents
Study: 11495449
Drug: Mycobacterium habana
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium habana vaccine (1.5 mg)
Study: 11495449
Drug: Mycobacterium habana
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium habana vaccine
Study: 7594346
Drug: Half-dose q.d.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose q.d. (30 mg/day)
Study: 7594346
Drug: Weekend full-dose
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekend full-dose (30 mg on weekends)
Study: 2643641
Drug: Karaya gum
Normalized name: Karaya Gum
DrugBank: Karaya gum (DB10535)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karaya gum patches containing salicylic acid
Study: 2643641
Drug: Control patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patches (without salicylic acid)
Study: 27614662
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy (CT) with adjunctive Memory Support Intervention (CT + Memory Support)
Study: 21762179
Drug: Ethanol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.5 mg/kg)
Study: 19481792
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop (self-etching adhesive)
Study: 18652266
Drug: One Step
Normalized name: One Step
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One Step (etch-and-rinse bonding agent)
Study: 12886826
Drug: CLD i.v.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLD i.v., 300 mg/2 weeks and oral calcium carbonate (500 mg x 2/day) and vitamin D3 (400 IU x 2/day)
Study: 12886826
Drug: CLD i.m.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLD i.m., 100 mg/week and the same doses of calcium and vitamin D3 as group A
Study: 10845828
Drug: CsA in
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA in a single daily dose
Study: 3818144
Drug: Pirenzepin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepin (20 mg intravenous injection)
Study: 31357402
Drug: Low-salt bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-salt bread (0.3 g salt/100 g) as part of a reduced-salt diet
Study: 25139150
Drug: Naftopidil 50
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 50 mg/day
Study: 25139150
Drug: Naftopidil 50
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 50 mg/day plus Celecoxib 200 mg
Study: 17631866
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX: 30, 50, or 70 mg)
Study: 17631866
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts extended-release (MAS XR: 10, 20, or 30 mg)
Study: 12045762
Drug: Fränkel Functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fränkel Functional Regulator‐II (FR‐II) treatment for 18 months
Study: 10208142
Drug: Nandrolone decanoate,
Normalized name: Nandrolone Decanoate, decanoate 50 mg/mL intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nandrolone decanoate, 100 mg by intramuscular injection once a week for 6 months
Study: 10208142
Drug: Placebo by
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by intramuscular injection once a week for 6 months
Study: 8903607
Drug: Non-potassium-sparing diuretics
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-potassium-sparing diuretics
Study: 8903607
Drug: Potassium-sparing diuretic
Normalized name: Potassium-sparing diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-sparing diuretic therapy
Study: 31280434
Drug: Panitumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panitumumab (6 mg/kg) plus docetaxel (50 mg/m2) and cisplatin (50 mg/m2) every 2 weeks until disease progression, unacceptable toxicity, or patient withdrawal
Study: 29582422
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg hyperbaric bupivacaine plus 15 μg fentanyl
Study: 29582422
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg hyperbaric bupivacaine
Study: 26402815
Drug: RVE with
Normalized name: Accu-Chek Comfort Curve with Lancets
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVE with high-protein supplement diet (NeX group)
Study: 23934737
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of ellagitannin-rich berries (specific dosage and duration not mentioned)
Study: 19060417
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg/day for 1 week)
Study: 19060417
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/day for 1 week)
Study: 19060417
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and fasudil (combination therapy)
Study: 19060417
Drug: Fasudil (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (selective Rho-kinase inhibitor)
Study: 19060417
Drug: Statins (atorvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins (atorvastatin, pitavastatin, pravastatin at 10 micromol/L)
Study: 8155929
Drug: Budesonide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (200 micrograms daily)
Study: 8155929
Drug: Budesonide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (800 micrograms daily)
Study: 27068361
Drug: Insulin analogues
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogues (detemir/aspart)
Study: 27068361
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (NPH/regular)
Study: 21105622
Drug: Heparin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (75 units/kg intravenously) before clamping of the artery
Study: 18997913
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + insertion of doxycycline gel (SRP+DH)
Study: 18997913
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + insertion of chlorhexidine gel (SRP+CHX)
Study: 12667121
Drug: Warfarin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin alone (INR of 2.8 IU)
Study: 12667121
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin (75 mg/day) and warfarin (INR of 2.2 IU)
Study: 12667121
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (160 mg/day)
Study: 12667121
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin and warfarin
Study: 10941621
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (300 mg) with kinnow juice (300 ml)
Study: 10941621
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release theophylline (300 mg) with water (300 ml)
Study: 7886617
Drug: High transfusion
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High transfusion rates with subcutaneous desferrioxamine injections (Group A)
Study: 7886617
Drug: Maintaining pretransfusion
Normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintaining pretransfusion Hb levels between 6-7 g/dl (Group C)
Study: 3522813
Drug: sorbinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorbinil (100 mg daily for 4 weeks)
Study: 31410338
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (10 gm two hours before radiotherapy, five days a week during the seven-week course)
Study: 31410338
Drug: Concurrent chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-radiotherapy with oral glutamine
Study: 26324049
Drug: Post-PCI Bivalirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-PCI Bivalirudin infusion
Study: 26324049
Drug: No post-PCI
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No post-PCI infusion
Study: 11116284
Drug: LJP-394, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJP-394, 100 mg intravenously weekly
Study: 3501751
Drug: Ofloxacin 100mg
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin 100mg single dose
Study: 26369563
Drug: Tiotropium Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Respimat® 5 μg
Study: 25458454
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution coloading (GroupC)
Study: 20462055
Drug: Modified Shegan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Shegan Mahuang Decoction (SGMH), one dose per day for 4 weeks
Study: 20462055
Drug: Montelukast, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, once a day for 4 weeks (4 mg for ages 2-5, 5 mg for ages 6-14)
Study: 12426013
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg IV
Study: 12426013
Drug: Meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 50 mg IV